Normal human development, disease risk, and response to treatments are often different in males and females. Cancer is no exception, and researchers are working to determine whether cancer treatments should be optimized independently for males and females. The goals of this project are to study the different mechanisms involved in male and female in pediatric neuroblastoma development and to further the knowledge of the genetic mechanisms involved in the development of cancers in both children and adults. The analysis of the Pediatric Brain Tumor Atlas data will be a critical component of moving this important line of investigation forward as it applies to the pediatric brain cancer population.
What are the goals of this project?
Researchers will investigate data on pediatric neuroblastoma in an effort to understand any differences found in male and female patients that could help calibrate future treatment protocol. Additionally researchers will further their knowledge of the genetic components involved in the development of cancers in both children and adults.
What is the impact of this project?
Researchers are working to determine whether cancer treatments should be optimized for male and female patients, and this research will provide insight into that question.
Why is the CBTN request important to this project?
The Pediatric Brain Tumor Atlas provides researchers with a broad and unique dataset for use in this research.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas
St. Louis Children's HospitalJoined on
Founded in 1879, St. Louis Children’s Hospital (SLCH) is at the forefront of pediatric medicine, providing care for children around the world. As the pediatric teaching hospital for Washington University School of Medicine (WUSM), SLCH offers nationally recognized programs for training and research.
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the